Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia.

By W. Wierda, T. Kipps, J. Mayer, S. Stilgenbauer, Cathy D. Williams, A. Hellmann, T. Robak, R. Furman, P. Hillmen, M. Trněný and 10 more. Journal of Clinical Oncology, 2010

608 citations recorded by the source corpus.

Subfields: Genetics, Oncology, Radiology, Nuclear Medicine and Imaging

View Paper: https://www.semanticscholar.org/paper/4404735b2163cb0c534eb3436cfcaf83d1419ed3

Citations in the corpus

• Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia (2014, neutral): “Urinary tract infection 19 (10) 7 (4) 10 (5) 1 (1)”
• Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia (2014, neutral): “Infusion-related reaction 17 (15) 0 30 (28) 4 (4)”